The Indian stock market continues to buzz with activity as several major companies release their quarterly results and announce strategic moves that could shape their future growth. Among the top stocks to watch today are Bharti Airtel, Gland Pharma, and Zydus Lifesciences. Each of these companies has recently made headlines for different reasons, from robust earnings growth to significant fundraising plans and steady operational performance.

In this article, we’ll dive deep into the latest updates from these market leaders, analyze their financial performance, and explore what these developments mean for investors.

Bharti Airtel: Strong Q2 Earnings and Market Momentum

Bharti Airtel has once again demonstrated its resilience and growth potential with its latest quarterly results. The telecom giant reported a consolidated net profit of ₹6,792 crore for the second quarter ended September 30, 2025, marking an impressive 89% year-on-year increase from ₹3,593 crore in the same period last year. This surge in profitability is a clear indicator of the company’s strong operational execution and market leadership.

Key Financial Highlights

• Revenue from operations stood at ₹52,145 crore, up 26% compared to ₹41,473 crore in Q2 FY25.
• EBITDA for the quarter was ₹29,919 crore, reflecting a 36% YoY growth, with EBITDA margins at 57.4%.
• Mobile ARPU increased to ₹256 from ₹233 in the previous year, signaling improved customer value and pricing power.
• The company’s customer base reached 624 million across 15 countries, with 450 million in India alone.

Bharti Airtel’s share price has also been on an upward trajectory, trading around ₹2,074 as of early November 2025. Over the past 12 months, the stock has gained 27.4%, and its market capitalization now stands at over ₹12.5 lakh crore. The company’s return on equity (ROE) for the year ending March 31, 2025, was 25.58%, significantly outperforming its five-year average of 8.59%.

What Investors Should Watch

• The company’s ability to sustain high ARPU and expand its customer base in both India and Africa.
• Continued investment in network infrastructure and digital services.
• Future dividend payouts and shareholder returns, given the company’s healthy dividend payout ratio of 38.8%.

Zydus Lifesciences: Fundraising Plans and Growth Prospects

Zydus Lifesciences is another stock making waves in the market, not just for its financial performance but also for its strategic moves. The company is scheduled to meet on November 6, 2025, to consider raising up to ₹5,000 crore through various routes, including qualified institutional placement (QIP), rights issue, preferential allotment, or private placement. This move is seen as a vote of confidence in the company’s growth plans and its ability to capitalize on new opportunities.

Recent Financial Performance

• Revenue from operations for Q1 FY26 was ₹6,574 crore, up 6% year-on-year.
• Net profit rose 3.3% to ₹1,467 crore, aided by a forex gain of ₹57 crore.
• EBITDA remained flat at ₹2,089 crore, with EBITDA margins narrowing to 31.8% from 33.6% a year ago.
• The company’s R&D investments for the quarter were ₹485.6 crore, representing 7.4% of revenues.

Zydus Lifesciences has also been active in the acquisition space, recently completing the stake acquisition in Amplitude Surgical SA, a European MedTech leader in high-quality, lower-limb orthopedic technologies. This acquisition is expected to add a sustainable growth driver for the company’s future.